mebendazole has been researched along with degrasyn in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR | 1 |
| Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR | 1 |
| Cao, BY; Chen, XH; Lin, P; Mao, XL; Wang, Q; Wang, XG; Xu, YJ; Zeng, YY; Zhang, T; Zhang, ZB | 1 |
3 other study(ies) available for mebendazole and degrasyn
| Article | Year |
|---|---|
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility | 2019 |
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States | 2020 |
Mebendazole elicits potent antimyeloma activity by inhibiting the USP5/c-Maf axis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cyanoacrylates; Drug Repositioning; Drug Synergism; Female; HEK293 Cells; Humans; Mebendazole; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; Proof of Concept Study; Protein Binding; Proto-Oncogene Proteins c-maf; Pyridines; Ubiquitin-Specific Proteases; Ubiquitination; Xenograft Model Antitumor Assays | 2019 |